Universität zu Köln

Al-Sawaf, Othman, Fischer, Kirsten, Engelke, Anja, Pflug, Natali, Hallek, Michael and Goede, Valentin (2017). Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. Drug Des. Dev. Ther., 11. S. 295 - 305. ALBANY: DOVE MEDICAL PRESS LTD. ISSN 1177-8881

Full text not available from this repository.

Abstract

For decades, treatment of chronic lymphocytic leukemia (CLL) has been based on chemotherapy. This changed when the first CD20 antibody rituximab was introduced. Since 2008, the combination of chemotherapy and CD20 antibodies has become the standard of care for most patients, and a significant fraction of patients had very long-lasting remissions after chemoimmunotherapy. Despite the improvement of response rates and overall survival (OS) by the use of chemoimmunotherapy, most CLL patients will relapse eventually. One approach to achieve more durable responses was the development of obinutuzumab (GA101), a new type of CD20 antibody that has unique molecular and functional characteristics. Obinutuzumab is a type II fully humanized CD20 antibody that binds to a partly different epitope of the CD20 protein than rituximab and due to its glycoengineered design induces greater antibody-dependent cell-mediated cytotoxicity (ADCC). Initial preclinical observations of a more effective B-cell depletion have been successfully reproduced in clinical trials with CLL patients. This review summarizes results of preclinical as well as clinical studies with obinutuzumab and provides an outlook on its future role in the therapy of CLL.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Al-Sawaf, Othman UNSPECIFIED UNSPECIFIED UNSPECIFIED Fischer, Kirsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Engelke, Anja UNSPECIFIED UNSPECIFIED UNSPECIFIED Pflug, Natali UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Goede, Valentin UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-243251
DOI:	10.2147/DDDT.S104869
Journal or Publication Title:	Drug Des. Dev. Ther.
Volume:	11
Page Range:	S. 295 - 305
Date:	2017
Publisher:	DOVE MEDICAL PRESS LTD
Place of Publication:	ALBANY
ISSN:	1177-8881
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language NON-HODGKIN-LYMPHOMA; B-CELL LYMPHOMA; ANTI-CD20 MONOCLONAL-ANTIBODY; HIGH-AFFINITY BINDING; PHASE-II GAUGUIN; CD20 ANTIBODY; OPEN-LABEL; PLUS CHLORAMBUCIL; IN-VITRO; RITUXIMAB Multiple languages Chemistry, Medicinal; Pharmacology & Pharmacy Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/24325